CEACAM5 and neoplasm: CEA-IL2v is designed to induce a local immune response in the tumor by binding preferentially to CEA-expressing tumor cells while avoiding activation of Tregs due to reduced IL-2Rα binding, which was confirmed in preclinical experiments [7].